aptam
vitro
select
dna
rna
molecul
capabl
bind
wide
rang
nucleic
nonnucl
acid
molecul
high
affin
specif
process
initi
librari
dna
rna
sequenc
incub
target
molecul
sequenc
highest
specif
affin
bound
target
other
remov
primari
sequenc
pool
select
molecul
recov
initi
dna
molecul
use
amplifi
polymeras
chain
reaction
pcr
rna
sequenc
revers
transcrib
vitro
cdna
similarli
dna
molecul
use
pcr
reaction
amplifi
oligonucleotid
put
addit
select
cycl
usual
selectionrepl
cycl
requir
obtain
highli
specif
aptam
receiv
aptam
isol
clone
sequenc
follow
valid
find
specif
target
aptam
highest
bind
affin
kd
dissoci
constant
apart
cancer
neurodegen
autoimmunolog
bacteri
diseas
current
anoth
signific
group
therapeut
target
ie
viral
infect
howev
decad
research
treatment
mani
viral
diseas
move
past
clinic
trial
reach
market
standard
therapi
satisfactori
enough
thu
aptam
could
potenti
use
detect
specif
viral
molecul
treatment
viral
infect
review
highlight
current
achiev
use
aptam
viral
infect
appropri
diagnosi
key
factor
treatment
viral
diseas
nevertheless
viral
infect
difficult
distinguish
especi
onset
acut
infect
appear
patient
present
set
nonspecif
sign
symptom
time
import
factor
rapidli
develop
epidemiolog
danger
diseas
influenza
ebola
sar
sever
acut
respiratori
syndrom
hand
chronic
viral
diseas
asymptomat
oligosymptomat
therapeut
success
focus
organ
protect
chronic
destruct
failur
eg
human
immunodefici
viru
hcv
hepat
c
viru
depend
earli
detect
infect
agent
twenti
year
sinc
aptam
construct
date
studi
exploit
viral
diseas
develop
enough
mostli
focus
wellknown
virus
hcv
hbv
hepat
b
viru
hpv
human
papilloma
viru
sar
influenza
studi
virus
carri
systemat
eg
occasion
experi
conduct
aptam
rift
valley
fever
dengu
differ
arbovirus
particular
attent
focus
influenza
diagnosi
due
high
risk
infect
remark
frequenc
mutat
result
cyclic
appear
new
viral
strain
epidem
even
pandem
danger
recent
avian
influenza
epidemiolog
challeng
diseas
character
sever
cours
high
mortal
rate
increas
risk
zoonot
influenza
strain
gener
capabl
move
one
person
anoth
hemagglutinin
ha
wellknown
influenza
protein
glycoprotein
express
high
amount
viral
surfac
respons
fusion
viru
host
cell
least
differ
ha
antigen
therefor
could
serv
infect
diagnosi
also
distinguish
current
influenza
type
subtyp
gopinath
et
al
construct
two
rna
aptam
specif
bind
type
b
ha
respect
aptam
abl
distinguish
influenza
type
type
b
even
close
relat
strain
influenza
subtyp
emphas
bind
target
molecul
viru
higher
affin
compar
convent
antiha
monoclon
antibodi
recent
also
construct
aptam
abl
detect
influenza
viru
type
well
avian
viru
thu
shown
aptam
recogn
danger
influenza
strain
high
epidemiolog
risk
howev
still
necessari
gener
simpl
avail
technic
order
increas
benefit
aptam
wang
li
gener
construct
abl
detect
avian
influenza
viru
assign
aptasensor
method
base
quartz
crystal
microbal
qcm
includ
attach
quartz
particl
polymer
porou
hydrogel
contain
dna
aptam
thought
similar
method
use
detect
human
infect
ebola
tombelli
et
al
gener
biosensor
base
spr
qcm
techniqu
introduc
aptam
capabl
detect
tat
protein
use
biotinstreptavidin
interact
approach
allow
high
specif
distinct
tat
rev
hiv
protein
structur
similar
tat
ruslinda
et
al
target
tat
molecul
use
biosensor
base
diamond
fieldeffect
transistor
fet
techniqu
anoth
import
field
aptam
applic
chronic
infect
caus
virus
hepat
b
c
aptam
specif
hcv
glycoprotein
obtain
park
et
al
invent
new
diagnost
testenzym
link
aptosorb
assay
elasa
allow
qualit
analysi
also
quantif
viru
particl
test
sampl
solut
could
use
ie
monitor
antivir
treatment
liu
et
al
investig
rna
aptam
recogn
hbsag
antigen
present
infect
hepatocyt
thu
possibl
find
hbv
infect
cell
wherea
former
assay
detect
antigen
purifi
form
import
influenc
viral
diagnost
develop
aptam
made
labib
et
al
construct
gold
microelectrod
impedimetr
properti
order
distinguish
biolog
activ
inact
form
viru
appli
heatinactiv
vaccinia
model
use
specif
dna
aptam
detect
presenc
viabl
viru
form
sinc
imped
lower
tang
et
al
use
viru
receiv
dna
aptam
capabl
distinguish
infect
human
cell
healthi
noninfect
counterpart
idea
base
presenc
unspecifi
membran
marker
appear
cell
surfac
similar
studi
carri
parekh
et
al
addit
defin
target
construct
aptam
glycosyl
ha
present
infect
cell
import
threat
human
health
due
oncogen
potenti
human
papilloma
viru
type
hpv
respons
approxim
cervic
cancer
case
direct
caus
molecul
viral
oncoprotein
necessari
develop
line
rapid
sensit
less
costli
diagnost
tool
identifi
type
viru
infect
well
detect
dysplast
endometri
cell
high
risk
malign
transform
consequ
hpv
potenti
target
aptam
toscanogaribay
et
al
use
vitro
select
obtain
rna
aptam
bind
viral
oncoprotein
part
biosensor
could
provid
power
diagnost
tool
graham
zarbl
receiv
fluorescentconjug
dna
aptam
abl
bind
superfici
determin
normal
cervic
epithelium
cell
initi
malign
transform
bind
aptam
bruno
et
al
gener
dna
aptam
direct
pathogen
arboviru
famili
includ
virus
chikungunja
crimeancongo
haemorrhag
fever
dengu
west
nile
tickborn
enceph
receiv
sequenc
high
specif
affin
purifi
recombin
viral
protein
whole
inact
virus
prove
valu
select
sequenc
project
diagnost
method
ie
later
flow
chromatograph
test
strip
fluoresc
aptamermagnet
bead
sandwich
assay
also
propos
aptam
use
passiv
immun
antivir
prophylaxi
low
immunogen
approach
could
promis
danger
infect
lack
effici
therapeut
altern
spread
dengu
fever
viru
caus
extend
occurr
host
aed
aegypti
mosquito
result
contemporari
climat
chang
fletcher
et
al
construct
three
modular
biosensor
allow
qualit
quantit
analysi
viral
infect
base
appear
fluoresc
biosensor
detect
viru
sensor
contain
follow
modul
sequenc
complementari
viral
genom
ii
sequenc
complementari
aptam
iii
aptamerecori
restrict
enzym
complex
iv
dna
motiv
bound
fluoresc
inhibitor
v
ecori
target
sequenc
vi
dna
fragment
label
fluoresc
dyer
primari
fluoresc
quench
inhibitor
aptam
bound
viral
genom
fragment
complementari
aptam
expos
conform
chang
biosensor
occur
ecori
releas
activ
enzym
cleav
dna
sequenc
stain
fluoresc
dyer
subsequ
appear
fluoresc
intens
proport
number
viral
copi
tabl
show
summari
describ
method
use
aptasensor
detect
virus
also
test
clinic
sampl
briefli
bai
et
al
took
attempt
combin
aptam
biosensor
technolog
known
spr
model
includ
chip
coat
gold
layer
streptavidin
dna
aptam
direct
avian
influenza
attach
surfac
sinc
modifi
biotinyl
materi
test
studi
saliva
harvest
poultri
method
requir
label
procedur
facilit
quick
h
detect
also
invent
new
costeffect
diagnost
method
enabl
earli
diagnosi
hcv
essenti
lee
et
al
report
construct
biosensor
util
fluoresc
dye
rna
aptam
direct
hcv
core
antigen
chen
et
al
obtain
aptam
bound
viral
glycoprotein
approach
might
crucial
earli
diagnosi
hepat
c
moment
window
period
serum
antibodi
appear
yet
commonli
fluoresc
dyeconjug
aptam
seem
use
varieti
diagnost
test
tabl
show
detail
inform
appli
solut
current
diagnost
standard
viral
infect
enzymelink
immunosorb
assay
elisa
molecular
biolog
test
commonli
use
elisa
multistag
procedur
consid
effici
enough
rel
low
sensit
well
high
rate
fals
posit
result
moreov
difficult
use
obligatori
applic
monoclon
antibodi
avail
viral
diseas
current
use
immunosorb
test
abl
detect
current
diseas
moment
specif
antibodi
format
direct
infect
agent
howev
specif
host
immun
develop
sever
week
month
origin
infect
problem
known
socal
window
period
addit
patient
receiv
immunosuppress
therapi
effect
antibodi
gener
may
occur
altern
routin
use
even
experiment
diagnost
molecular
test
allow
direct
detect
alien
genet
materi
without
wait
immun
respons
host
furthermor
advantag
molecular
assay
extrem
high
sensit
abl
detect
singl
viral
copi
andor
earli
viral
transcript
immedi
onset
infect
unfortun
due
high
cost
complic
procedur
necess
employ
highli
skill
staff
rare
perform
aptam
seem
appropri
respons
problem
describ
present
attract
altern
current
use
procedur
due
high
specif
affin
bind
viral
antigen
low
cost
product
use
biosensor
equip
aptam
anoth
research
techniqu
use
molecul
allow
detect
earli
genet
materi
viral
protein
late
host
antibodi
infect
marker
furthermor
aptam
enabl
distinguish
infect
host
cell
infect
one
may
help
recogn
activ
form
viru
tabl
compar
standard
diagnost
techniqu
use
detect
influenza
hbv
hiv
note
mani
case
use
current
avail
diagnost
tool
number
disadvantag
could
easili
avoid
use
aptam
moreov
aptamerbas
minimum
threshold
detect
sometim
lower
rtpcr
case
influenza
viru
hand
detect
threshold
similar
even
higher
compar
current
use
techniqu
aptam
ensur
increas
sensit
specif
diagnost
test
nevertheless
time
diagnosi
also
signific
shown
tabl
detect
time
influenza
viru
use
aptasensorbas
techniqu
remark
shorter
method
due
rapid
growth
popul
differ
varieti
virus
frequent
resist
standard
therapeut
treatment
clearli
urgent
need
develop
new
diagnost
method
character
high
sensit
specif
allow
earli
rapid
pathogen
detect
biosensor
technolog
probabl
rapidli
grow
area
current
diagnosist
viral
diseas
aptam
perfect
exampl
molecular
recognit
biosensor
element
product
cost
low
comparison
monoclon
antibodi
also
provid
sensit
specif
construct
biosensor
believ
aptamerbas
biosensor
could
appli
promis
approach
specif
issu
could
use
cheap
diagnosi
earli
stage
diseas
ie
immedi
exposur
pathogen
well
monitor
treatment
process
selex
versatil
suscept
modif
enhanc
select
pressur
could
allow
obtain
aptam
detect
precis
level
viremia
threshold
current
use
diagnost
method
moreov
aptamerbas
approach
ensur
rapid
cheaper
diagnosi
aptam
structur
might
major
constraint
futur
applic
diagnost
tool
mani
exist
aptam
rna
molecul
highli
suscept
degrad
nucleas
consequ
use
molecularrecognit
element
biosensor
may
limit
problem
solv
synthes
mirror
analog
particl
retain
origin
properti
cleav
nucleas
altern
solut
includ
local
modif
ribos
site
aptam
chain
conclus
believ
aptam
molecul
potenti
attract
viral
diagnost
lifethreaten
common
viral
diseas
includ
hcv
sar
mer
middl
east
respiratori
syndrom
mention
avian
flu
variant
eg
reason
ineffici
medic
vaccin
includ
high
viru
mutat
variabl
low
specif
avoid
host
immun
respons
also
must
rememb
mani
exist
antivir
drug
caus
side
effect
may
lead
develop
diseas
initi
treat
also
interact
varieti
medicin
may
weaken
enhanc
primari
activ
mani
method
use
treatment
viral
infect
partial
effect
exampl
standard
treatment
hcv
ribavirin
interferonalpha
effect
case
wherea
million
patient
die
everi
year
problem
basi
search
new
therapeut
tool
effect
simultan
less
danger
patient
one
potenti
promis
solut
might
aptam
direct
protein
infect
cell
viral
compon
aptam
might
use
treat
infect
also
prevent
itvir
infect
inhibit
almost
step
diseas
mani
studi
confirm
effect
therapeut
strategi
block
penetr
virus
cell
andor
inhibit
enzym
involv
replic
also
believ
aptam
abl
select
stimul
immun
system
suitabl
subject
structur
modif
vivo
biostabl
improv
conjug
therapeut
molecul
small
interf
rna
sirna
ribozym
figur
high
variabl
viral
genom
region
common
caus
viru
resist
current
use
therapi
thu
requir
gener
aptam
specif
highli
conserv
nucleic
acid
region
mutat
appear
rel
rare
attent
paid
hcv
infect
due
preval
sever
complic
wellknown
therapeut
problem
viral
diseas
consid
aptam
target
includ
influenza
hsv
herp
simplex
viru
hbv
infect
ie
diseas
commonli
occur
immun
antivir
respons
tabl
show
detail
inform
experi
describ
subsect
present
one
obviou
frequent
studi
therapeut
strategi
inhibit
viral
fusion
target
cell
virus
penetr
cell
use
specif
surfac
protein
serv
ligand
superfici
human
molecul
commonli
known
mani
virus
show
tropism
specif
cell
type
ie
hcv
hbv
glycoprotein
ligand
helper
cell
receptor
inhibit
dey
et
al
use
rna
aptam
shorter
variant
moreov
block
bind
cell
coreceptor
cc
chemokin
receptor
type
observ
decreas
concentr
antigen
supernat
virusinfect
cultur
human
pbmc
peripher
blood
mononuclear
cell
measur
elisa
assay
number
viru
copi
qpcr
quantit
realtim
pcr
assay
mutat
analysi
show
aptam
bound
highli
conserv
region
hcv
infect
glycoprotein
potenti
target
aptam
approach
coreceptor
human
present
hepatocyt
b
lymphocyt
chen
et
al
construct
dna
aptam
assign
competit
block
major
hcv
serotyp
use
prove
human
establish
cell
line
hepatocellular
carcinoma
decreas
viral
rna
level
qrtpcr
revers
transcriptionqpcr
analysi
protein
concentr
western
blot
assay
demonstr
anoth
applic
relat
conservedha
region
influenza
viru
jeon
et
al
select
dna
aptam
bound
ha
specif
site
respons
ligat
human
cell
receptor
aptamerdepend
prevent
viral
fusion
target
cell
confirm
vitro
cultur
establish
madindarbi
canin
kidney
mdck
cell
line
measur
viabil
cell
exposur
influenza
viru
aport
cell
viabil
increas
depend
manner
concentr
cell
cultur
best
effect
observ
pmol
therapeut
potenti
also
evalu
experiment
anim
model
mice
infect
influenza
strain
threat
aptamerbas
drug
tend
lose
weight
slower
nontreat
control
group
infiltr
mononuclear
cell
lung
alveoli
reduc
treat
mice
exposit
choi
et
al
select
anoth
aptam
specif
avian
influenza
viru
prove
capac
inhibit
viral
infect
mdck
cell
dosedepend
manner
mtt
assay
cheng
et
al
investig
randomli
select
dna
aptam
aptam
strongli
bound
subunit
danger
strain
avian
influenza
viru
demonstr
mtt
assay
mdck
cell
cultur
applic
aptam
slow
progress
infect
author
emphas
aptam
applic
might
persuad
host
immun
system
gain
time
gener
effect
antivir
respons
two
rna
aptam
assign
similar
mechan
action
recent
select
wang
et
al
adopt
strategi
human
cytomegaloviru
hcmv
infect
obtain
two
rna
aptam
direct
superfici
viral
ligand
glycoprotein
b
h
aptam
reduc
cytomegaloviru
infect
proven
human
foreskin
fibroblast
hff
cell
line
cultur
preincub
aptam
expos
hcmv
viral
particl
inhibit
viral
plaqu
format
cultur
observ
administr
nm
nm
aptam
respect
author
also
found
bind
site
aptam
differ
recogn
specif
monoclon
antibodi
aptam
design
gopinath
et
al
inhibit
viral
glycoprotein
ligand
actual
hsv
entri
mediat
receptor
hvem
initi
select
aptam
long
nt
reduc
nt
modifi
improv
biostabl
reduc
infecti
potenti
observ
aptam
dosedepend
manner
plaqu
format
test
african
green
monkey
kidney
vero
cell
cultur
select
aptam
cytotox
effect
half
maxim
inhibitori
concentr
calcul
importantli
signific
aptam
specif
allow
distinguish
strain
anoth
strategi
effect
compar
block
viral
fusion
cell
inhibit
enzym
protein
involv
viral
replic
transcript
translat
hcv
viral
protein
nonstructur
protein
rnadepend
rna
polymeras
promis
target
aptam
treatment
signific
viru
replic
hcv
singl
strand
rna
viru
biroccio
et
al
select
rna
aptam
character
stemloop
structur
specif
sequenc
uauggaccaguggc
recogn
key
elementa
gtp
bind
site
function
inhibit
polymeras
activ
posit
correl
aptam
concentr
vitro
analysi
polymeras
activ
shown
bellecav
et
al
obtain
dna
aptam
direct
enzym
block
activ
anoth
way
ie
competit
polymerasebind
site
viral
rna
templat
select
aptam
administr
cultur
cell
reduc
quantiti
viral
rna
hcvpermiss
human
hepatoma
cell
line
infect
hcv
strain
reveal
qrtpcr
comparison
nonaptam
treat
cell
hcv
rna
copi
reduct
viru
rna
level
aptam
concentr
nm
observ
respect
despit
absenc
transfect
agent
aptam
molecul
found
intracellularli
proven
confoc
microscopi
feng
et
al
investig
antihbv
rna
aptam
design
crucial
moment
hbv
replic
assembl
interact
viral
protein
r
rnadepend
rna
polymeras
stemloop
structur
sequenc
locat
side
pregenom
rna
interact
viral
polymeras
high
affin
compet
bind
site
viral
genet
materi
inhibit
hbv
replic
reduct
replic
intermedi
human
infect
cell
line
assess
southern
blot
analysi
cell
line
transfect
plasmid
vector
encod
rna
aptam
destefano
nair
confirm
vitro
effect
dna
aptam
direct
revers
transcriptas
hiv
strain
aptam
similar
one
mention
compet
natur
templat
bind
site
enzym
subsequ
inhibit
viral
replic
observ
prove
vitro
primer
extens
assay
reaction
rate
decreas
presenc
nm
nm
aptam
respect
except
polymeras
enzym
indirectli
involv
viru
replic
best
known
protein
nonstructur
protein
consist
two
domain
cand
ntermin
one
helicas
proteas
activ
respect
domain
essenti
replic
flavivirida
famili
includ
hcv
proteas
domain
convert
viral
protein
necessari
life
cycl
helicas
unwind
dna
rna
duplex
allow
replic
genet
materi
polymeras
physiolog
condit
helicas
domain
affin
poli
u
sequenc
locat
region
viral
genom
umehara
et
al
gener
bival
aptam
sequenc
connect
poli
u
linker
seri
experi
determin
optimum
length
linker
ie
nt
result
aptam
highest
simultan
reduct
helicas
proteas
activ
obtain
confirm
vitro
enzymat
assay
valu
proteas
helicas
domain
inhibit
nm
nm
aptam
respect
anoth
studi
fukuda
et
al
use
rna
aptam
also
equip
sequenc
poli
u
inhibit
activ
proteas
helicas
domain
assess
vitro
enzymat
test
vivo
hela
cell
cultur
effect
signific
aptam
dosedepend
hypothes
aptam
compet
region
hcv
genom
bind
site
helicas
domain
anoth
protein
necessari
replic
assembl
hcv
virion
nonstructur
protein
aptam
obtain
yu
et
al
allow
inactiv
infect
cell
exposit
aptam
viral
rna
level
onefold
decreas
comparison
nontreat
aptam
control
assess
realtim
pcr
particular
demonstr
coupl
aptam
allow
new
activ
virion
product
prove
ffu
focu
form
assay
naiv
cell
sixfold
decreas
virusposit
foci
observ
naiv
cell
infect
supernat
harvest
cell
cultur
treat
aptam
comparison
nontreat
control
approach
seem
safe
antivir
interferon
cell
mechan
remain
inact
mrna
product
interferon
gene
quantifi
qrtpcr
similar
observ
safeti
profil
note
gao
et
al
found
induct
interferon
gene
express
realtim
pcr
assay
obtain
aptam
direct
protein
nonstructur
protein
hcv
abl
effect
inhibit
viral
replic
one
discov
protein
lifethreaten
coronaviru
sar
nonstructur
protein
enzym
ntpasehelicas
activ
function
similar
flavivirida
proteinit
unwind
viral
dsdna
jang
et
al
target
appli
specif
rna
aptam
secondari
structur
contain
stemloop
structur
ag
repeat
vitro
analysi
inhibit
viral
enzym
activ
dosedepend
manner
baselin
valu
nm
confirm
fluoresc
reson
energi
transfer
fret
test
progress
viral
infect
prevent
inhibit
nucleocapsid
synthesi
typic
therapeut
target
gag
protein
nucleocapsid
low
variabl
compar
sequenc
genom
ramalingam
et
al
use
antigag
rna
aptam
infect
cell
cultur
observ
nearli
decreas
number
virion
releas
outsid
cell
examin
cultur
supernat
aptam
reduc
cellular
level
mrna
gag
impair
virion
releas
cell
confirm
elisa
western
blot
assay
proper
function
aptam
base
competit
packag
signal
nucleocapsid
bind
site
interestingli
previou
studi
kim
et
al
select
rna
aptam
activ
similar
way
bound
two
differ
sequenc
region
rich
gc
gu
circul
aptam
enhanc
biostabl
effect
bind
affin
examin
spr
thu
aptam
seem
especi
promis
therapeut
tool
opportun
select
aptam
target
molecul
protein
make
possibl
use
viral
nucleic
acid
certain
region
genom
interact
protein
respons
transcript
initi
translat
replic
viral
assembl
gener
aptam
select
affin
region
seem
promis
therapeut
approach
intern
ribosom
entri
site
ire
hcv
mrna
involv
viral
translat
potenti
attract
therapeut
target
due
conserv
sequenc
ire
compos
four
domain
iiv
locat
region
respons
initi
viral
replic
mrna
capindepend
translat
ire
bind
small
ribosom
subunit
host
cell
eukaryot
translat
initi
factor
konno
et
al
appli
rna
aptam
direct
domain
ire
locat
end
viral
genom
antisens
strand
inhibit
hcv
genet
materi
replic
vitro
analysi
consensu
sequenc
complementari
loop
domain
respons
effect
way
prevent
attach
viral
rna
polymeras
mention
kikuchi
et
al
obtain
rna
aptam
contain
loop
structur
consensu
sequenc
complementari
loop
ire
domain
ii
vitro
translat
test
iresluciferas
mrna
confirm
decreas
luciferas
activ
presenc
aptam
team
anoth
studi
develop
aptam
direct
iiid
domain
ire
success
inhibit
viral
vitro
iresdepend
translat
seem
much
effici
aptam
target
second
domain
iresdecreas
luciferas
activ
control
level
observ
inhibit
potenti
select
molecul
also
prove
hela
cell
model
cultur
transfect
pmol
aptam
show
decreas
luciferas
activ
particular
attent
focus
simultan
inhibit
ire
domain
ii
iiiiv
especi
iiid
iiie
region
seem
crucial
hcv
translat
subsequ
two
aptam
conjug
form
show
stronger
bind
affin
target
sequenc
compon
alon
also
valu
respons
decreas
translat
activ
lower
moreov
romerolopez
et
al
combin
activ
hammer
head
ribozym
properti
typic
aptam
construct
assign
bound
ire
domain
iiid
cleav
hcv
genom
side
led
simultan
inhibit
viral
translat
replic
effect
prove
human
cell
harbor
subgenom
rna
replicon
deriv
viral
sens
strand
synthesi
inhibit
nearli
assess
qrtpcr
assay
mutat
analysi
show
inhibitori
effect
depend
typic
antihcv
rna
activ
enzymat
ribozym
cleavag
activ
well
attempt
focus
aptam
bind
long
termin
repeat
ltr
known
ltr
sequenc
necessari
proper
express
viral
gene
specif
aptam
would
inhibit
process
srisawat
engelk
obtain
aptam
respect
activ
therapeut
effect
subject
intens
examin
interest
strategi
viral
infect
applic
aptam
specif
messeng
oligonucleotid
therapeut
effect
small
interf
rna
molecul
use
construct
aptamersirna
would
limit
specif
therapi
fraction
target
cell
select
recogn
aptam
moreov
could
reduc
side
effect
accompani
type
therapi
liu
et
al
construct
fluorescein
isothiocyan
fitc
conjug
rna
aptam
specif
surfac
antigen
hbsag
hbv
infect
cell
detect
infect
cell
fluoresc
microscopi
postul
replac
fitc
particl
therapeut
agent
futur
zhou
neff
et
al
went
one
step
design
chimer
construct
compos
aptam
sirna
molecul
direct
mrna
tatrev
protein
model
cho
chines
hamster
ovari
cell
line
cell
author
confirm
bind
abil
fluorescentlylabel
aptam
viral
protein
chimera
penetr
cell
sirna
molecul
appear
intracellularli
prove
flow
cytometri
confoc
microscopi
second
phase
appear
sirna
molecul
insid
express
ccrfcem
human
cell
lymphoblastlik
cell
line
cell
confirm
northern
blot
therapeut
potenti
confirm
decreas
tatrev
mrna
express
qrtpcr
reaction
propos
solut
extrem
benefici
aptam
alon
also
show
inhibitori
effect
viru
infect
therapeut
effect
therefor
strengthen
neff
et
al
renew
studi
use
human
mice
raghu
infect
chimera
ch
biostabl
mous
serum
improv
modif
aptam
initi
aptam
dose
detect
h
incub
mice
serum
reduct
viral
activ
observ
chimera
applic
author
prove
reduct
tatrev
mrna
transcript
level
mice
lymphocyt
qrtpcr
also
find
differ
percentag
cell
infect
mice
compar
uninfect
control
consequ
prove
protect
activ
construct
chimera
vivo
model
raghu
mice
use
test
aptam
modifi
f
gcrich
sequenc
addit
linker
modif
allow
noncoval
simultan
bind
transport
three
differ
sirna
molecul
direct
tatrev
protein
molecul
use
chimera
result
lower
viral
activ
assess
qpcr
assay
total
plasma
viral
load
infect
mice
moreov
viru
undetect
threeweek
treat
five
eight
mice
observ
previou
experi
construct
protect
anim
reduct
lymphocyt
popul
differ
strategi
chosen
zhu
et
al
convert
rna
aptam
dna
aptam
combin
sirna
molecul
direct
mrna
proteas
fluoresc
label
aptamersirna
conjug
uptak
confirm
fluoresc
microscopi
inhibit
effect
character
decreas
mrna
proteas
express
cell
transfect
pcdnahivpr
plasmid
prove
qrtpcr
assay
moreov
comparison
rna
aptam
dna
counterpart
seem
effici
sirna
deliveri
aim
anoth
studi
gener
aptamersirna
chimera
could
prevent
human
cell
infect
use
two
chimera
aptamerantigagsirna
also
bruno
et
al
signal
possibl
effect
aptam
block
congo
hemorrhag
fever
dengu
fever
tickborn
enceph
west
nile
viru
infect
anoth
approach
propos
hwang
et
al
gener
rna
aptam
stimul
innat
antivir
immun
specif
bound
cytosol
receptor
rigi
retino
acidinduc
gene
respons
foreign
molecular
pattern
recognit
infect
cell
result
enhanc
antivir
respons
includ
product
accord
vitro
observ
aptam
help
prevent
cell
invas
prior
appli
mani
exist
viral
infect
human
anim
still
consid
incur
base
recent
year
experi
exclud
new
danger
also
lifethreaten
virus
best
current
exampl
ebola
viru
perceiv
sever
threat
global
public
health
less
year
sinc
epidem
viru
spread
west
coast
africa
mani
experi
still
conduct
discov
vaccin
enhanc
determin
find
new
therapeut
diagnost
solut
necessari
date
two
report
contribut
aptam
potenti
tool
ebola
diagnosi
treatment
huang
et
al
investig
aptam
capabl
bind
zincfing
antivir
protein
respons
inter
alia
inhibit
ebola
viru
replic
select
aptam
contain
conserv
sequenc
gggugg
gaggg
loop
region
import
specif
interact
aptam
antivir
protein
inform
could
serv
base
design
molecular
diagnost
test
capabl
detect
ebola
mrna
bin
et
al
use
selex
obtain
aptam
direct
protein
ebola
viru
one
import
protein
viru
replic
complex
element
rnadepend
rna
polymeras
select
molecul
abl
compet
viral
dsrna
bind
protein
therefor
could
disrupt
interact
ebola
nucleoprotein
refer
exampl
present
articl
aptam
seem
effect
therapeut
agent
limit
amplif
virion
block
penetr
target
cell
howev
initi
success
present
studi
conduct
vitro
anim
model
fulli
evalu
therapeut
potenti
molecul
question
biostabl
pharmacodynam
well
deliveri
cell
address
consid
therapeut
potenti
aptam
must
consid
least
competitor
low
eg
sirna
highmolecular
weight
molecul
eg
monoclon
antibodi
undoubt
advantag
sirna
molecul
interact
aptam
wide
spectrum
potenti
target
molecul
target
sirna
intracellular
rna
particl
aptam
could
also
link
molecul
locat
extracellularli
present
blood
cell
surfac
target
extracellular
molecul
elimin
need
involv
indirect
factor
provid
aptam
transport
cell
membran
although
result
mani
studi
show
util
aptam
act
extracellular
space
would
suffici
reduc
extent
viral
infect
deliveri
target
cell
could
give
better
chanc
final
cure
infect
still
remain
challeng
howev
similar
problem
occur
case
sirna
solut
might
gene
therapi
techniqu
particular
associ
viral
gene
transfer
effect
approach
proven
eg
anim
model
noteworthi
studi
carri
bellecav
et
al
aptam
abl
penetr
cell
without
involv
addit
carrier
unfortun
mechan
action
still
remain
unclear
howev
gene
therapi
actual
branch
experiment
medicin
leav
question
answer
necess
proof
safeti
shown
viral
vector
introduc
cell
may
lead
insert
mutagenesi
andor
develop
diseas
initi
treat
hand
wide
use
monoclon
antibodi
effect
extracellular
target
penetr
insid
cell
therefor
interest
solut
could
applic
aptam
highlyspecif
therapeut
carrier
nucleic
acid
molecul
ribozym
sirna
hiv
experi
conduct
zhou
et
al
neff
et
al
one
hand
high
specif
aptam
allow
deliveri
sirna
cell
actual
requir
treatment
sirna
penetr
cell
receptormedi
endocytosi
solv
problem
use
indirect
factor
ensur
transport
drug
cell
membran
wide
spectrum
target
ligand
unquestion
advantag
aptam
make
competit
solut
aptam
associ
extracellular
target
first
clinic
practic
intracellular
target
howev
aptam
activ
reduc
hydrophil
featur
subsequ
seem
obviou
number
necessari
analyz
must
carri
prove
safeti
intracellular
deliveri
vector
encod
aptam
predict
probabl
first
futur
clinic
trial
aptam
concern
viral
neutral
easili
access
area
organ
ie
upper
respiratori
tract
lower
airway
femal
reproduct
organ
direct
surfac
marker
pathogen
quit
attract
method
applic
would
aerosol
contain
aptam
eg
case
influenza
viru
interest
perspect
outlin
wheeler
et
al
intravagin
applic
gelcream
contain
chimer
aptamersirna
might
protect
hiv
infect
less
import
factor
aptam
treatment
stabil
physiolog
condit
wildtyp
nucleic
acid
moleculesdna
particular
rnaar
sensit
exonucleas
activ
perform
therapeut
function
natur
unchang
form
griffin
et
al
consid
unmodifi
aptam
direct
target
exist
blood
may
character
halflif
time
less
min
order
improv
aptam
halflif
time
seri
variou
chemic
modif
highlight
introduc
structur
one
interest
approach
invert
nucleotid
side
aptam
obtain
two
end
aptam
becom
resist
activ
dominantli
occur
extracellular
environ
anoth
modif
lead
enhanc
stabil
aptam
variou
chang
ribos
site
anoth
challeng
aptam
clinic
applic
apart
unsatisfactori
biostabl
fast
renal
clearanceth
time
aptam
resid
circul
short
intens
excret
renal
filtrat
main
factor
caus
fast
clearanc
low
molecular
weight
usual
exceed
kda
emphas
cutoff
threshold
renal
filtrat
approxim
kda
problem
could
solv
conjug
oligonucleotid
cholesterol
molecul
macromolecular
polym
exampl
polyethylen
glycol
peg
similar
studi
antivir
activ
aptam
howev
result
obtain
experi
inter
alia
aptam
tightli
bind
blood
coagul
factor
ixa
halflif
extend
min
h
show
method
would
effect
case
antivir
aptam
well
undoubt
advantag
aptam
contrast
monoclon
antibodi
lose
primari
properti
modif
recent
one
aptamerbas
drugmacugenha
enter
clinic
trial
gain
market
approv
therefor
number
report
possibl
side
effect
product
rel
small
research
shown
conjug
compos
aptam
peg
highmolecular
weight
compound
may
lead
infrequ
product
neutral
antibodi
direct
polym
subsequ
rapid
filtrat
conjug
kidney
abil
antisens
oligonucleotid
andor
therapeut
substanc
carri
accumul
interior
particularli
phagocyt
cell
also
report
undoubtedli
aptam
molecul
extraordinari
potenti
possibl
obtain
tool
specif
even
unknown
destin
target
make
extrem
attract
import
aptam
select
specif
antivir
molecul
exhibit
actual
activ
infect
cell
howev
none
select
antivir
aptam
enter
phase
clinic
trial
real
import
continu
studi
lifethreaten
acut
viral
infect
ebola
avian
influenza
sar
prioriti
problem
consist
danger
chronic
viral
diseas
hiv
hbv
hcv
clinic
trial
need
focu
actual
efficaci
antivir
aptam
aptam
singl
strand
nucleic
acid
molecul
consist
dna
rna
bind
organ
nonorgan
molecul
high
specif
affin
aptam
gener
method
refer
systemat
evolut
ligand
exponenti
enrich
selex
properti
aptam
make
competit
monoclon
antibodi
use
convent
laboratori
practic
first
pharmaceut
aptam
macugen
pegaptanib
sodium
admit
us
agenc
food
drug
administr
fda
treatment
agerel
macular
degener
amd
success
treatment
viral
diseas
depend
earli
detect
infect
agent
aptam
allow
detect
earli
viral
gene
protein
late
antibodi
produc
host
infect
marker
strategi
enabl
differenti
infect
host
cell
uninfect
one
aptam
differenti
activ
inact
viru
form
tw
conceiv
review
topic
gener
figur
wrote
manuscript
jw
conduct
tabl
wrote
manuscript
pk
correct
edit
manuscript
author
read
approv
final
manuscript
author
declar
conflict
interest
